HIV/AIDS News and Research RSS Feed - HIV/AIDS News and Research Twitter

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

This condition progressively reduces the effectiveness of the immune system and leaves individuals susceptible to opportunistic infections and tumors. HIV is transmitted through direct contact of a mucous membrane or the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, preseminal fluid, and breast milk.
Kaiser Permanente study: Self-reported exercise lowers blood pressure, blood glucose levels

Kaiser Permanente study: Self-reported exercise lowers blood pressure, blood glucose levels

Self-reported moderate to vigorous exercise was associated with lower blood pressure and blood glucose levels in a Kaiser Permanente study published in the journal Preventing Chronic Disease. [More]
Research findings may lead to new treatment strategies for Ewing sarcoma

Research findings may lead to new treatment strategies for Ewing sarcoma

The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes - both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. These findings by Massachusetts General Hospital investigators, published in the November issue of Cancer Cell, may lead to new therapies targeting these aberrant mechanisms. [More]
Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers from Intermountain Medical Center in Salt Lake City have identified a new "sliding scale" model used to rule out potentially deadly blood clots in the lungs, known as pulmonary embolisms, that is more accurate than current diagnostic methods. [More]
EGPAF to receive $63 million UNITAID grant to improve early infant diagnosis of HIV programs

EGPAF to receive $63 million UNITAID grant to improve early infant diagnosis of HIV programs

The Elizabeth Glaser Pediatric AIDS Foundation is pleased to announce that it has been selected by the UNITAID Executive Board to receive up to $63 million in funding to improve early infant diagnosis (EID) of HIV programs in nine African countries. This investment will pave the way for universal access to HIV testing and enable a ten-fold increase in HIV treatment, thus transforming the effort to end AIDS in children worldwide. [More]
Researchers explore lifespan variability between races

Researchers explore lifespan variability between races

Eliminating health disparities between races is a goal of many groups and organizations, but a team of sociologists suggests that finding the reasons for the differences in the timing of black and white deaths may be trickier than once thought. [More]
Scientists validate oral vaccine delivery system to combat global health threats

Scientists validate oral vaccine delivery system to combat global health threats

Scientists at The Forsyth Institute and Tufts University have succeeded in describing and validating a unique system of oral vaccine delivery using a common bacteria found in the mouth. [More]

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C. [More]
Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. [More]

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
Alere Determine HIV-1/2 Ag/Ab Combo test receives CLIA Waiver from FDA

Alere Determine HIV-1/2 Ag/Ab Combo test receives CLIA Waiver from FDA

Alere Inc., a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA (Clinical Laboratory Improvement Amendments) Waiver for the Alere Determine™ HIV-1/2 Ag/Ab Combo test. [More]
New study investigates rate of HIV testing in patients with mental illnesses

New study investigates rate of HIV testing in patients with mental illnesses

People with mental illness are more likely to have been tested for HIV than those without mental illness, according to a new study from a team of researchers at Penn Medicine and the U.S. Centers for Disease Control and Prevention published online this week in AIDS Patient Care and STDs. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
New WHO guidance provides cervical cancer control and prevention approach

New WHO guidance provides cervical cancer control and prevention approach

New guidance from WHO aims to help countries better prevent and control cervical cancer. The disease is one of the world's deadliest - but most easily preventable - forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries. [More]
UCLA researchers devise plan to reduce HIV transmission in Africa

UCLA researchers devise plan to reduce HIV transmission in Africa

While Ebola has attracted much of the world's attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually. [More]

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Mylan Inc. and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and people worldwide who are living with or at risk of HIV/AIDS. [More]

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs. [More]
HIV drugs could be harnessed to treat leading cause of blindness

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure. [More]
New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million. [More]